{"id":949636,"date":"2026-04-07T16:34:50","date_gmt":"2026-04-07T20:34:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/"},"modified":"2026-04-07T16:34:50","modified_gmt":"2026-04-07T20:34:50","slug":"vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/","title":{"rendered":"Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN CARLOS, Calif., April  07, 2026  (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET \/ 11:15 a.m. PT.<\/p>\n<p>A live webcast of the fireside chat can be accessed through the Investors &amp; Media section of the Company\u2019s website at http:\/\/investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.<\/p>\n<p>\n        <strong>About Vaxcyte\u00a0<\/strong><br \/>\n        <br \/>Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company\u2019s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company\u2019s PCV franchise.<\/p>\n<p>Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF<sup>\u00ae<\/sup>, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company\u2019s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte\u2019s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Fwk80AgSFWeIRDPqS_7P1g8FEwR5panlHer8bMuJ-KqYavpOKWKOkUn1C4aTykVvmN0jdKcxWImlzWzQdO-3EY62p9uZPXgg9rfcBJ30UqaItwo6j0sPX3lFtA3GCh9W4Hn2HEvI9LRIw4I2-oT68I-IixOyCQuWfVHw34gXw9OQNl821322Emr87GaqmlDOXBKvV59rccd4fkgLFDkji78-w9QN4D3ONkcYviPEph6rO9Uh3OjtqDHYfDGihAAWNnLNm1GScVV72skhFH3uUcTxJ7NtjfsWisRCN6R5I50yB5lxdz1pqbHS3s2Xng7yeFCQF2GXwcvIX_RMQ18jiCuALtqmyK3ZaYFaFyRGaDYwOsHp0CLMfMnxkGm5i4K9E0ohio4bZQdAudBCkRqVnnfuzjm3uDNzX4UFuytQWbTSYmGOrzFrLTqVAAYJnc-svB1TWbs1fFVTHsZZ7ONrbR7nQ5LOYG3gXkaZq7A0E6LU6kRRbPHNHhh-FYw5Hzc3Y59Lt6_ltPucHHghw7QoAl111oVvwC-ALmfzxN_U-z-v0luQmC1oLh-IZ_HJGPdQUyyEE5KkABLyyIBOS5qS0tjaBSh1jiV4ILX6akxEkGd-wFDgVhn_urBx0UQbu28ziBJhr2l6XmsjGWhyZucaTtWKsIuUK76M0C8TUEBx85wk2UPHy5Zo5E-JvnaD4fxwgmkrMewm0nL4vu7gPTEcIVxIMPibBKkLfWC19l7JmGxxS---svqBdMhdhQcNPDW5EWRKusVwxbF9-1m2xl1AC2bVGpu1eY1BqCzNdDcTCvV7PVxIXC4YtGZgvb8q2mAMWYNsNjuTVgUI-7ixAnICP29NqTaFJMVPOgMwnSR4w0_cLfTLf2-s-pXEQrSJ_EdcY_f6tmtyvmlhaZrHaA4aD5F8tbDo5rTnh5iNbccfauHbCgrAXyfSiZxYRQPZd-ff7y4mg0z_WtYg-CFrnw2p5ORc9zqerB0ryhSDrYMGYkciRd_WKoLcvYtJtqwGJCp0c--g3Eyr1sx-fZAnyyWj2632popPT3dQGlJSaGJujbCo6c_T6BnQgWtJ3jlHWcec_JhIbnYt1mSVr1PafuyYQmKDloAYe1IhDrdUv3bRdKdAh9nQQ00DFdnL-z3u9v8Hd7vLNpclndYplL_UEato3lFW2eoUa64zKY1Rc_qPLwqrU6VDKfUF3E3djHLmi6SPySKlU8SZn80J915X0T9eXWXgEw-_wy5mzTPc_E7IaAWhZ5SaBmr-72PlKm6XAfgIPRu6asTXd91zpmUHzoFntvZJeEkUhQkhbxLEFcnujv-XQeuQlpcWL6waonobqoEdikKF0fndREfnPhkO-U8pS-XoMnxFLue-sN7e-Nzt6rOQVsjH27TKppToAa9ueld_3ixh26CiEJSTj387wYaoOcAvzskzJgxM1Y3jLInihiEGASlaLd9mlZ-4pwp-7TYCw7OzE78K9Cz0RjpCYHCCcU5XjVpLf5Oy7c3Y2dNH1JmtuCw9TN8_PsFeXUj9ZcpzW8F5QV3kQQak0zyg7gMqHCI6PidNDnmxxUTkKGE5Cjc=\" rel=\"nofollow\" target=\"_blank\">www.vaxcyte.com<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <u>Contact:<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>Jeff Macdonald, Executive Director, Investor Relations<br \/>Vaxcyte, Inc.<br \/>917-371-0940<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uKoWWlzsreetdLewz7Y5Yt4_LLw1PJdv5NFUhANVAxC0C5h9SxZLzSc0ddlDVxupPxaENhV9GBrXKSAHUCQDsHLeiYxx4iMlSm7T45FVua03maPrkQfTcsfGgMZH1wv4I7zdkh9gOX4anaavABIktwlcnLrF2gK-Jq7dLvHlPNJDI218AUfBXDG-zk96C9XoJrlP3E0CA-Ixq65qRi4iWy-qJXDcqnMM_Ka_xoOzmfkcMTKZABIfBhje5qUsgkZrzor70_jusSWwumu9huQnJQ==\" rel=\"nofollow\" target=\"_blank\">investors@vaxcyte.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDY4NCM3NTIxMjMwIzIxOTU4MjQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjBhOTQxMDgtMmVkMC00NTViLTlhZmItMGUxZjIzNWY4ZWNhLTEyMDczNzctMjAyNi0wNC0wNy1lbg==\/tiny\/Vaxcyte-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET \/ 11:15 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors &amp; Media section of the Company\u2019s website at http:\/\/investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About Vaxcyte\u00a0 Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949636","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET \/ 11:15 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors &amp; Media section of the Company\u2019s website at http:\/\/investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About Vaxcyte\u00a0 Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS &hellip; Continue reading &quot;Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-07T20:34:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDY4NCM3NTIxMjMwIzIxOTU4MjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference\",\"datePublished\":\"2026-04-07T20:34:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/\"},\"wordCount\":346,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDY4NCM3NTIxMjMwIzIxOTU4MjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/\",\"name\":\"Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDY4NCM3NTIxMjMwIzIxOTU4MjQ=\",\"datePublished\":\"2026-04-07T20:34:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDY4NCM3NTIxMjMwIzIxOTU4MjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDY4NCM3NTIxMjMwIzIxOTU4MjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference - Market Newsdesk","og_description":"SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET \/ 11:15 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors &amp; Media section of the Company\u2019s website at http:\/\/investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About Vaxcyte\u00a0 Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS &hellip; Continue reading \"Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-07T20:34:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDY4NCM3NTIxMjMwIzIxOTU4MjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference","datePublished":"2026-04-07T20:34:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/"},"wordCount":346,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDY4NCM3NTIxMjMwIzIxOTU4MjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/","name":"Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDY4NCM3NTIxMjMwIzIxOTU4MjQ=","datePublished":"2026-04-07T20:34:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDY4NCM3NTIxMjMwIzIxOTU4MjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDY4NCM3NTIxMjMwIzIxOTU4MjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949636","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949636"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949636\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949636"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949636"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949636"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}